Moleculin Biotech is trading 7.93% up at $10.00; no confirmed company-specific announcement explaining the October 28 move was found. - The latest identified company update was an October 20 CEO Corner segment about its MIRACLE trial. - Biotech-sector strength may be supportive: XBI rose 2.18% during the regular session amid positive trial and regulatory news. This is context, not a confirmed direct cause of the stock’s larger gain.